This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Click here for Trumenba®▼ (meningococcal group B vaccine (recombinant, adsorbed)) Prescribing Information for Great Britain (GB) and Northern Ireland (NI). Black triangle status is applicable in Great Britain. Adverse event reporting information can be found at the bottom of the page.
Trumenba (meningococcal group B vaccine (recombinant, adsorbed)) is indicated for active immunisation of individuals 10 years and older to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B.1
Trumenba is a vaccine composed of 2 recombinant lipidated factor H binding protein (fHbp) variants.1 fHbp is found on the surface of meningococcal bacteria and helps bacteria to avoid host immune defences.
fHbp variants segregate into 2 immunologically distinct subfamilies, A and B.1 Over 91%** of MenB strains express sufficient levels of fHbp subfamily A or B to be susceptible to bactericidal killing by Trumenba induced antibodies.
**A survey of over 2,150 different invasive meningococcal serogroup B isolates collected from 2000-2014 in 7 European countries, the US and Canada demonstrated that over 91% of all meningococcal serogroup B isolates expressed sufficient levels of fHbp to be susceptible to bactericidal killing by vaccine-induced antibodies.1.
2-dose schedule1
This includes 2 doses (0.5ml each) administered 6 months apart.
3-dose schedule1
This includes 2 doses (0.5ml each) administered at least 1 months apart, followed by a third dose at least 4 months after the second dose.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021